Nanotechnology for neurodegenerative disorders.

The efficacy, cellular uptake and specific transport of drugs and/or imaging agents to target organs, tissues and cells are common issues in the diagnosis and treatment of different disorders. In the case of neurodegenerative diseases, they represent complex problems, since brain targeting remains a still unsolved challenge in pharmacology, due to the presence of the blood-brain barrier, a tightly packed layer of endothelial cells that prevents unwanted substances to enter the brain. Engineered nanomaterials, objects with dimensions of 1-100 nm, are providing interesting biomedical tools potentially able to solve these problems, thanks to their physico-chemical features and to the possibility of multi-functionalization, allowing to confer them different features at the same time, including the ability to cross the blood-brain barrier. This review focuses on the state-of-the-art of nanomaterials suitable for therapy and diagnostic imaging of the most common neurodegenerative disorders, as well as for neuroprotection and neuronal tissue regeneration. Finally, their potential neurotoxicity is discussed, and future nanotechnological approaches are described.

[1]  M. Das,et al.  Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. , 2007, Biomaterials.

[2]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[3]  Giuseppe Trapani,et al.  Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. , 2011, International journal of pharmaceutics.

[4]  Mark A. Smith,et al.  Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. , 2009, Progress in brain research.

[5]  P. Antich,et al.  Nanoparticulate Radiolabelled Quinolines Detect Amyloid Plaques in Mouse Models of Alzheimer's Disease , 2010, International journal of Alzheimer's disease.

[6]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Patrick Couvreur,et al.  Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. , 2007, Biomacromolecules.

[8]  Thomas Wisniewski,et al.  Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging , 2011, NeuroImage.

[9]  Simon Labrecque,et al.  Microglial response to gold nanoparticles. , 2010, ACS nano.

[10]  Vasilis Ntziachristos,et al.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging , 2010, Particle and Fibre Toxicology.

[11]  J. Kreuter,et al.  Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Jingyun Wang,et al.  Cytotoxicity of single-walled carbon nanotubes on PC12 cells. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[13]  M. Masserini,et al.  Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[14]  R. Boado A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery. , 2008, Drug news & perspectives.

[15]  P. Andjus,et al.  Molecular imaging of brain lipid environment of lymphocytes in amyotrophic lateral sclerosis using magnetic resonance imaging and SECARS microscopy. , 2011, Physiological research.

[16]  Doriano Brogioli,et al.  Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.

[17]  E. Norrby,et al.  Prions and protein‐folding diseases , 2011, Journal of internal medicine.

[18]  Paresh Chandra Ray,et al.  Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. , 2009, ACS nano.

[19]  Linyin Feng,et al.  Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model , 2010, Journal of the Neurological Sciences.

[20]  Tin-Tin Win-Shwe,et al.  Nanoparticles and Neurotoxicity , 2011, International journal of molecular sciences.

[21]  Meicheng Yang,et al.  A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of α-synuclein. , 2010, Chemistry.

[22]  R. Béné,et al.  Nano-HPLC–MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients—a pilot study , 2010, Analytical and bioanalytical chemistry.

[23]  G. Giammona,et al.  Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. , 2010, Nanomedicine.

[24]  Mark A. Smith,et al.  Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease , 2009, Neuroscience Letters.

[25]  V. Pillay,et al.  Advances in the treatment of neurodegenerative disorders employing nanotechnology , 2010, Annals of the New York Academy of Sciences.

[26]  L. Ghasemi‐Mobarakeh,et al.  Electrospun composite nanofibers for tissue regeneration. , 2011, Journal of nanoscience and nanotechnology.

[27]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[28]  N. Cole,et al.  The cell biology of alpha-synuclein: a sticky problem? , 2002, Neuromolecular medicine.

[29]  M. Masserini,et al.  The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. , 2011, Biomaterials.

[30]  S. Krol,et al.  A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated gold nanoparticles. , 2010, Nanoscale.

[31]  E. Kosenko,et al.  Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. , 2007, Journal of nanoscience and nanotechnology.

[32]  C. Lemere,et al.  Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  M. Gobbi,et al.  Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. , 2011, Biomaterials.

[34]  Y. Lim,et al.  The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. , 2010, Biomaterials.

[35]  N. Cole,et al.  The cell biology of α-synuclein , 2007, NeuroMolecular Medicine.

[36]  C. Fernandes,et al.  Nano-interventions for neurodegenerative disorders. , 2010, Pharmacological research.

[37]  Guang-Zhen Jin,et al.  Neurite outgrowth of dorsal root ganglia neurons is enhanced on aligned nanofibrous biopolymer scaffold with carbon nanotube coating , 2011, Neuroscience Letters.

[38]  G. Zaharchuk,et al.  Delivery of imaging agents into brain. , 1999, Advanced drug delivery reviews.

[39]  Ezzie Hutchinson,et al.  Systems neuroscience: The stress of dieting , 2011, Nature Reviews Neuroscience.

[40]  Morteza Mahmoudi,et al.  Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. , 2011, ACS nano.

[41]  Jun-Jian Liu,et al.  Peripheral nerve regeneration using composite poly(lactic acid-caprolactone)/nerve growth factor conduits prepared by coaxial electrospinning. , 2011, Journal of biomedical materials research. Part A.

[42]  D. Pang,et al.  PEG-interspersed nitrilotriacetic acid-functionalized quantum dots for site-specific labeling of prion proteins expressed on cell surfaces. , 2010, Biomaterials.

[43]  M. Masserini,et al.  Liposomes functionalized with acidic lipids rescue Aβ-induced toxicity in murine neuroblastoma cells , 2011, Alzheimer's & Dementia.

[44]  S. Krol,et al.  Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. , 2010, Nanoscale.

[45]  Ru Bai,et al.  Rutile TiO₂ particles exert size and surface coating dependent retention and lesions on the murine brain. , 2011, Toxicology letters.

[46]  Itamar Willner,et al.  Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: assays for the detection of neurotransmitters and of tyrosinase activity. , 2005, Analytical chemistry.

[47]  Li Feng,et al.  Fluorescence imaging of APP in Alzheimer's disease with quantum dot or Cy3: a comparative study. , 2010, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[48]  C. Mirkin,et al.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[50]  C. Schmidt,et al.  Nerve Growth Factor-Immobilized Electrically Conducting Fibrous Scaffolds for Potential Use in Neural Engineering Applications , 2012, IEEE Transactions on NanoBioscience.

[51]  Ping Ping Hu,et al.  Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. , 2010, Analytical chemistry.

[52]  Mayur M. Patel,et al.  Getting into the Brain , 2009, CNS Drugs.

[53]  R. Borgens,et al.  Polymer and nano-technology applications for repair and reconstruction of the central nervous system , 2012, Experimental Neurology.

[54]  G. Bačić,et al.  Imaging cellular markers of neuroinflammation in the brain of the rat model of amyotrophic lateral sclerosis. , 2011, Acta physiologica Hungarica.

[55]  C. Lemere,et al.  Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid , 2003, The Journal of Neuroscience.

[56]  Y. Lyubchenko,et al.  Early Stages for Parkinson’s Development: α-Synuclein Misfolding and Aggregation , 2009, Journal of Neuroimmune Pharmacology.

[57]  C. Epstein,et al.  A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. , 2004, Free radical biology & medicine.